Jenburkt Pharmaceuticals Ltd

jenburkt.com BSE: 524731
About

Jenburkt Pharmaceuticals is engaged in the business of Pharmaceuticals Formulation.

Key Points

One of the manufactures of Favipiravir
Jenburkt pharma is one of the companies that manufacture the COVID -19 drug Favipiravir by the name FAVIVENT.
Favipiravir is approved by DCGI (Drugs Controller General of India) under accelerated approval process considering the emergency situation of the COVID-19 outbreak for restricted use in the country.

See full details
Website BSE
  • Market Cap ₹ 224 Cr.
  • Current Price ₹ 488
  • High / Low ₹ 570 / 350
  • Stock P/E 11.1
  • Book Value ₹ 215
  • Dividend Yield 2.09 %
  • ROCE 23.8 %
  • ROE 18.5 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 25.67%

Cons

  • The company has delivered a poor sales growth of 3.15% over past five years.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Sep 2018 Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
31.98 32.28 35.13 20.84 34.18 33.59 30.28 17.43 30.48 31.82 29.56 27.18
24.90 25.91 26.22 21.46 26.76 26.94 23.99 16.81 23.31 24.80 24.53 21.82
Operating Profit 7.08 6.37 8.91 -0.62 7.42 6.65 6.29 0.62 7.17 7.02 5.03 5.36
OPM % 22.14% 19.73% 25.36% -2.98% 21.71% 19.80% 20.77% 3.56% 23.52% 22.06% 17.02% 19.72%
Other Income 0.90 0.67 0.93 1.24 0.86 0.83 1.29 0.98 1.02 1.05 1.26 1.19
Interest 0.09 0.11 0.10 0.07 0.19 0.14 0.12 0.11 0.12 0.12 0.12 0.10
Depreciation 0.33 0.35 0.35 0.53 0.54 0.66 0.57 0.49 0.51 0.51 0.53 0.43
Profit before tax 7.56 6.58 9.39 0.02 7.55 6.68 6.89 1.00 7.56 7.44 5.64 6.02
Tax % 24.07% 32.07% 26.62% -200.00% 26.49% 30.39% 32.95% -1.00% 25.00% 20.16% 31.38% 22.76%
Net Profit 5.74 4.46 6.89 0.06 5.55 4.64 4.62 1.01 5.67 5.95 3.88 4.65
EPS in Rs 12.51 9.72 15.01 0.13 12.09 10.11 10.07 2.20 12.35 12.96 8.45 10.13
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 TTM
51 57 60 69 76 85 94 103 115 123 119 109 119
45 47 50 59 65 70 77 84 91 98 99 89 94
Operating Profit 6 10 9 10 12 15 16 20 24 25 20 20 25
OPM % 13% 18% 16% 15% 15% 18% 18% 19% 21% 20% 17% 18% 21%
Other Income 1 0 1 1 2 2 3 3 3 3 4 4 5
Interest 1 1 1 1 1 0 0 0 0 0 1 0 0
Depreciation 1 1 1 1 2 3 2 2 2 1 2 2 2
Profit before tax 6 9 9 9 10 14 17 20 25 27 21 22 27
Tax % 34% 34% 30% 30% 27% 33% 36% 34% 32% 26% 30% 24%
Net Profit 4 6 6 6 8 10 11 14 17 20 15 16 20
EPS in Rs 8.13 12.95 12.91 13.38 16.15 20.76 23.19 29.06 37.50 43.14 32.40 35.95 43.89
Dividend Payout % 37% 27% 27% 31% 32% 30% 31% 28% 24% 24% 25% 28%
Compounded Sales Growth
10 Years:7%
5 Years:3%
3 Years:-2%
TTM:3%
Compounded Profit Growth
10 Years:11%
5 Years:9%
3 Years:-1%
TTM:27%
Stock Price CAGR
10 Years:20%
5 Years:6%
3 Years:-9%
1 Year:36%
Return on Equity
10 Years:26%
5 Years:24%
3 Years:22%
Last Year:18%

Balance Sheet

Figures in Rs. Crores

Corporate actions Corp actions Equity History
Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
5 5 5 5 5 5 5 5 5 5 5 5
Reserves 6 10 14 18 23 29 36 50 57 73 75 94
Borrowings 5 2 2 5 2 7 5 6 0 7 3 4
11 19 19 22 15 21 12 16 16 18 21 18
Total Liabilities 27 36 40 49 44 61 58 76 77 103 104 120
7 10 13 14 14 12 12 11 10 10 12 11
CWIP 1 1 0 0 0 0 0 0 0 1 0 0
Investments 1 1 1 0 0 0 1 2 5 5 4 7
18 24 26 34 30 49 45 64 62 87 88 103
Total Assets 27 36 40 49 44 61 58 76 77 103 104 120

Cash Flows

Figures in Rs. Crores

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
5 7 7 5 11 9 8 10 16 13 15 19
-1 -3 -3 -1 0 1 -0 -10 1 -11 -3 -19
-4 -2 -2 0 -7 1 -5 1 -18 -2 -11 -1
Net Cash Flow 0 2 2 3 5 11 2 1 -1 0 1 -0

Ratios

Figures in Rs. Crores

Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Debtor Days 27 31 22 32 26 32 23 32 40 68 55 47
Inventory Days 92 105 116 123 93 107 109 128 73 99 120 92
Days Payable 91 82 42 49 59 54 44 72 44 66 58 44
Cash Conversion Cycle 29 54 97 106 61 85 88 89 69 101 117 95
Working Capital Days 24 56 44 53 10 18 26 32 25 57 43 30
ROCE % 42% 60% 48% 40% 41% 42% 40% 39% 42% 37% 26% 24%

Shareholding Pattern

Numbers in percentages

Insider trades
Dec 2018 Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
45.60 45.60 45.60 45.65 45.73 45.73 45.73 45.73 45.73 45.73 45.73 45.73
2.11 2.22 2.22 2.22 2.22 2.22 2.22 2.22 2.22 2.57 4.37 4.37
0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
52.28 52.18 52.18 52.14 52.04 52.05 52.05 52.05 52.05 51.70 49.90 49.90

Documents

Recent announcements


View all

Annual reports

Credit ratings